K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies

Chimeric antigen receptor (CAR)-based therapy is of interest for relapsed or refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphomas. A prominent target antigen for this is the receptor CD7, which is expressed in ∼95% of T-ALL, ∼50% of peripheral T cell lymphomas, as well a...

Full description

Saved in:
Bibliographic Details
Main Authors: Nienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, Maurien G. Pruis, Lena Rockstein, Harm Jan Lourens, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
K12
ligand-based CAR-T
CD7-positive malignancy
AML
T-ALL
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329925000578
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950329925000578

Similar Items